[go: up one dir, main page]

NO20060093L - Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav - Google Patents

Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav

Info

Publication number
NO20060093L
NO20060093L NO20060093A NO20060093A NO20060093L NO 20060093 L NO20060093 L NO 20060093L NO 20060093 A NO20060093 A NO 20060093A NO 20060093 A NO20060093 A NO 20060093A NO 20060093 L NO20060093 L NO 20060093L
Authority
NO
Norway
Prior art keywords
methods
glycoprotein
plate
fusion polypeptides
variant fusion
Prior art date
Application number
NO20060093A
Other languages
English (en)
Inventor
Gray D Shaw
Ravindra Kumar
Dianne S Sako
Jin Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20060093L publication Critical patent/NO20060093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen frembringer sammensetninger og fremgangsmåter for å behandle eller forebygge vaskulærassosierte sykdommer.
NO20060093A 2003-06-11 2006-01-06 Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav NO20060093L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47752503P 2003-06-11 2003-06-11
PCT/US2004/019057 WO2004111089A2 (en) 2003-06-11 2004-06-14 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20060093L true NO20060093L (no) 2006-03-01

Family

ID=33551724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060093A NO20060093L (no) 2003-06-11 2006-01-06 Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav

Country Status (15)

Country Link
US (2) US7727535B2 (no)
EP (2) EP1636266A2 (no)
JP (1) JP2007537710A (no)
KR (1) KR20060022261A (no)
CN (1) CN100436480C (no)
AU (1) AU2004247737B2 (no)
BR (1) BRPI0411289A (no)
CA (1) CA2530972A1 (no)
IL (2) IL172337A (no)
MX (1) MXPA05013509A (no)
NO (1) NO20060093L (no)
NZ (1) NZ544165A (no)
RU (1) RU2403262C2 (no)
WO (1) WO2004111089A2 (no)
ZA (1) ZA200510331B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DE102007031708A1 (de) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
EP2193373A4 (en) 2007-08-23 2010-07-28 Bloodct Of Wisconsin Inc METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR
BR112014011758A2 (pt) * 2011-11-15 2017-05-09 The Walter And Eliza Hall Inst Of Medical Res composição farmacêutica, proteína de fusão, polinucleotídeo, vetor, célula isolada, métodos para produzir uma proteína de fusão, para tratar ou previnir uma doença ou condição, para diagnosticar a suscetibilidade de um indivíduo a desenvolver uma doença ou condição, para determinar uma adequabilidade do indivíduo para ingressar em um experimento de classificação dedroga, e para identificar um agente, uso de uma combinação, e, combinação.
WO2013096932A1 (en) * 2011-12-23 2013-06-27 Vasculogics, Inc. Compositions and methods for treatment of thrombosis and prolonging survival of stored platelets
EP2919013B1 (de) * 2014-03-11 2016-11-02 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Detektion von Modulatoren der GPIb-Thrombin-Interaktion
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
ES2984653T3 (es) * 2018-02-20 2024-10-30 Hoffmann La Roche Composición que comprende proteína del receptor GPIba recombinante
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (en) * 2021-07-29 2023-02-02 The University Of Birmingham Protein interaction inhibitors
EP4455160A4 (en) * 2021-12-15 2025-12-10 Shanghai Synvida Biotechnology Co Ltd PRODUCT AND METHOD OF TREATMENT FOR THROMBOCYTOPENIA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340727A (en) 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
IL88308A0 (en) 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
US4899195A (en) * 1988-01-29 1990-02-06 Ushio Denki Method of exposing a peripheral part of wafer
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US5194743A (en) * 1990-04-06 1993-03-16 Nikon Corporation Device for positioning circular semiconductor wafers
JP2874280B2 (ja) * 1990-05-16 1999-03-24 株式会社ニコン 周縁露光装置及び周縁露光方法
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5317097A (en) 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
TW316322B (no) * 1995-10-02 1997-09-21 Ushio Electric Inc
JP3237522B2 (ja) * 1996-02-05 2001-12-10 ウシオ電機株式会社 ウエハ周辺露光方法および装置
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
WO1999054360A1 (en) 1998-04-23 1999-10-28 Ajinomoto Co., Inc. Substance with antithrombotic activity and method for detecting glycokallidin
AR035779A1 (es) 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos

Also Published As

Publication number Publication date
BRPI0411289A (pt) 2006-08-01
CA2530972A1 (en) 2004-12-23
RU2403262C2 (ru) 2010-11-10
KR20060022261A (ko) 2006-03-09
AU2004247737A1 (en) 2004-12-23
IL172337A (en) 2012-07-31
NZ544165A (en) 2008-12-24
CN100436480C (zh) 2008-11-26
MXPA05013509A (es) 2006-04-05
WO2004111089A2 (en) 2004-12-23
US7727535B2 (en) 2010-06-01
US20050089888A1 (en) 2005-04-28
WO2004111089A3 (en) 2005-05-12
ZA200510331B (en) 2007-03-28
EP1636266A2 (en) 2006-03-22
JP2007537710A (ja) 2007-12-27
RU2006100306A (ru) 2006-06-10
IL220272A0 (en) 2012-07-31
EP2522677A1 (en) 2012-11-14
HK1095152A1 (zh) 2007-04-27
CN1823090A (zh) 2006-08-23
US20110039780A1 (en) 2011-02-17
AU2004247737B2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
IL214325A (en) Antibody against cmet, a drug that includes and uses it
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
DE602004026113D1 (de) Glp-1-verbindungen
GB2430677A8 (en) Novel antigenbinding polypeptides and their uses
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
UA89734C2 (en) ANTAGONISTS of muscarinic acetylcholine receptors
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
NO20034056D0 (no) Proliferative sykdommer
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
NO20060093L (no) Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
DE60206512D1 (de) Rapanycin29-enole
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
DE602005026169D1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
UY28344A1 (es) Nuevos compuestos
ATE409188T1 (de) Naphthyridinverbindungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application